title: Edible Ginger-derived Nano-lipids Loaded with Doxorubicin as a Novel Drug-delivery Approach for Colon Cancer Therapy.
abstract: The use of nanotechnology for drug delivery has shown great promise for improving cancer treatment. However, potential toxicity, hazardous environmental effects, issues with large-scale production, and potential excessive costs are challenges that confront their further clinical applications. Here, we describe a nanovector made from ginger-derived lipids that can serve as a delivery platform for the therapeutic agent doxorubicin (Dox) to treat colon cancer. We created nanoparticles from ginger and reassembled their lipids into ginger-derived nanovectors (GDNVs). A subsequent characterization showed that GDNVs were efficiently taken up by colon cancer cells. Viability and apoptosis assays and electric cell-substrate impedance-sensing technology revealed that GDNVs exhibited excellent biocompatibility up to 200 μmol/l; by contrast, cationic liposomes at the same concentrations decreased cell proliferation and increased apoptosis. GDNVs were capable of loading Dox with high efficiency and showed a better pH-dependent drug-release profile than commercially available liposomal-Dox. Modified GDNVs conjugated with the targeting ligand folic acid mediated targeted delivery of Dox to Colon-26 tumors in vivo and enhanced the chemotherapeutic inhibition of tumor growth compared with free drug. Current experiments explore the feasibility of producing nature-derived nanoparticles that are effective as a treatment vehicle while potentially attenuating the issues related to traditional synthetic nanoparticles.
authors: Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.|Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia, USA.
authors: Mingzhen
authors: M
authors: Zhang
authors: Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.|Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia, USA.|Institute for Clean Energy and Advanced Materials, Faculty for Materials and Energy, Southwest University, Chongqing, People's Republic of China.
authors: Bo
authors: B
authors: Xiao
authors: Center for Molecular and Translational Medicine, Georgia State University, Atlanta, Georgia, USA.
authors: Huan
authors: H
authors: Wang
authors: Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.|Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia, USA.
authors: Moon Kwon
authors: MK
authors: Han
authors: Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.|Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia, USA.
authors: Zhan
authors: Z
authors: Zhang
authors: Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.|Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia, USA.
authors: Emilie
authors: E
authors: Viennois
authors: Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.|Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia, USA.|The 2nd Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.
authors: Changlong
authors: C
authors: Xu
authors: Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.|Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia, USA.|Veterans Affairs Medical Center, Decatur, Georgia, USA.
authors: Didier
authors: D
authors: Merlin
mesh_terms: D000818:Animals; D017209:Apoptosis; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D004337:Drug Carriers; D016503:Drug Delivery Systems; D020939:Zingiber officinale / Q000737:chemistry*; D019073:HT29 Cells; D006801:Humans; D008055:Lipids / Q000737:chemistry*; D051379:Mice; D053758:Nanoparticles / Q000008:administration & dosage / Q000737:chemistry*; D023041:Xenograft Model Antitumor Assays
chemical_list: D004337:Drug Carriers; D008055:Lipids; D004317:Doxorubicin